Renagel: reducing serum phosphorus in haemodialysis patients - PubMed (original) (raw)
Review
Renagel: reducing serum phosphorus in haemodialysis patients
S K Burke. Hosp Med. 2000 Sep.
Abstract
Approximately half of all dialysis patients experience persistent hyperphosphataemia, which causes significant problems. Renagel is a calcium-free, aluminium-free phosphate binder which reduces serum phosphorus in haemodialysis patients by reducing absorption of dietary phosphorus. This article reviews the management of hyperphosphataemia and presents some Renagel clinical trial data.
Similar articles
- Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK. Goldberg DI, et al. Nephrol Dial Transplant. 1998 Sep;13(9):2303-10. doi: 10.1093/ndt/13.9.2303. Nephrol Dial Transplant. 1998. PMID: 9761513 Clinical Trial. - RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
Slatopolsky EA, Burke SK, Dillon MA. Slatopolsky EA, et al. Kidney Int. 1999 Jan;55(1):299-307. doi: 10.1046/j.1523-1755.1999.00240.x. Kidney Int. 1999. PMID: 9893140 Clinical Trial. - Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Chertow GM, et al. Am J Kidney Dis. 1997 Jan;29(1):66-71. doi: 10.1016/s0272-6386(97)90009-3. Am J Kidney Dis. 1997. PMID: 9002531 Clinical Trial. - Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
Cizman B. Cizman B. Nephrol Dial Transplant. 2003 Jul;18 Suppl 5:v47-9. doi: 10.1093/ndt/gfg1046. Nephrol Dial Transplant. 2003. PMID: 12817070 Review. - Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
Nolan CR, Qunibi WY. Nolan CR, et al. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. doi: 10.1097/00041552-200307000-00005. Curr Opin Nephrol Hypertens. 2003. PMID: 12815333 Review.
Cited by
- Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease.
Barreto FC, de Oliveira RB, Benchitrit J, Louvet L, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Riser BL, Massy ZA. Barreto FC, et al. J Bone Miner Metab. 2014 Nov;32(6):636-44. doi: 10.1007/s00774-013-0541-y. Epub 2014 Jan 21. J Bone Miner Metab. 2014. PMID: 24442863
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical